HistoSonics Raises New Financing to Expand Histotripsy Platform Across Solid Tumors
HistoSonics, the medical technology company behind the Edison® Histotripsy System, has closed a new financing round backed by Reed Jobs and Yosemite along with several additional strategic investors, strengthening the company’s push to broaden the clinical and commercial reach of its non-invasive tumor destruction platform. While the company did not disclose the amount raised, the financing comes at a time of strong momentum for HistoSonics as it expands the use of histotripsy in liver tumors and advances additional applications in kidney, pancreas, and other solid tumors. The company said the new round values HistoSonics at $3.75 billion. (Via Ritzau)
The investment marks another major milestone for a company that has rapidly emerged as one of the most closely watched names in device-based oncology. HistoSonics has spent the past several years building clinical and commercial traction around histotripsy, a novel therapeutic approach that uses focused ultrasound and acoustic cavitation to mechanically destroy targeted tissue without the need for surgery, needles, heat-based ablation, or radiation. The platform is being positioned as a new category of non-invasive therapy for solid tumors, with the potential to offer patients a treatment option that may reduce procedural burden and avoid some of the toxicities and recovery challenges associated with conventional interventions.
According to HistoSonics, the proceeds from the latest financing will be used to support continued commercial expansion, ongoing clinical development programs, new regulatory initiatives, and further progress across the company’s growing pipeline of histotripsy applications. The timing is notable: the company is already commercializing its liver tumor indication, has filed with the U.S. Food and Drug Administration for kidney tumor clearance, and is continuing to build clinical evidence in pancreatic tumors, one of the most difficult and underserved areas in oncology. (Via Ritzau)
Strategic Investors Join as HistoSonics Builds a Multi-Organ Histotripsy Franchise
HistoSonics framed the financing as more than a capital raise, emphasizing the strategic value of the investors joining the company at this stage of growth. Chairman and CEO Mike Blue said the company is focused on building a “generational” business and sees long-term strategic alignment as essential as it works to establish histotripsy as a new therapeutic platform across multiple tumor types. In his view, the latest financing adds investors who understand both the company’s mission and the scale of the commercial and clinical opportunity ahead.
One of the most high-profile additions to the syndicate is Reed Jobs, through Yosemite, an investment platform with the stated goal of helping “make cancer non-lethal in our lifetime.” Jobs described the backing of HistoSonics as both a mission-driven and personal investment, highlighting the company’s work in developing a new way to address some of the world’s deadliest cancers and diseases. He said Yosemite is focused on accelerating technologies that can meaningfully improve outcomes for patients, and sees HistoSonics as a pioneer in a field that could ultimately expand histotripsy throughout the body. (Via Ritzau)
The financing continues a remarkable run of capital formation for HistoSonics. In August 2025, the company was acquired in a $2.25 billion majority-stake transaction led by a syndicate of private and public investors, and in October 2025 it announced an oversubscribed $250 million growth financing backed by investors including Bezos Expeditions, Founders Fund, K5 Global, Thiel Bio, and Wellington Management. With the latest round, HistoSonics is clearly positioning itself for an accelerated growth phase that goes well beyond its initial liver tumor franchise. (MassDevice)
Histotripsy Moves Beyond Liver as the Company Broadens Its Ambitions
The financing comes as HistoSonics continues to gain traction in the treatment of liver tumors, the first clinical area where its Edison Histotripsy System has achieved commercial use. The device received FDA De Novo clearance in October 2023 for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. Since then, HistoSonics has worked to expand adoption among physicians and health systems in the United States and internationally, with growing use at leading academic medical centers and major hospitals. (HistoSonics)
Liver has served as the company’s initial beachhead, but HistoSonics’ ambitions extend much further. Over the past year, the company has accelerated both commercial and clinical activity in liver tumor treatment, including metastatic disease, while simultaneously pushing forward with new organ applications. The next major regulatory inflection point may come in the kidney setting. HistoSonics recently submitted a De Novo request to the FDA seeking clearance of the Edison system for the destruction of kidney tumors, a move that could open a significant new market for histotripsy and broaden the platform’s clinical footprint in urologic oncology. (Via Ritzau)
The company is also building clinical experience in pancreatic tumors, an area with profound unmet need where treatment options remain limited and outcomes are often poor. HistoSonics has indicated that it is advancing toward a future FDA submission for pancreatic applications as it reaches additional clinical and technical milestones. If successful, that effort could extend histotripsy into one of oncology’s most difficult tumor types and help define the platform not simply as a liver technology, but as a multi-organ therapeutic modality for solid tumors.
A Non-Invasive Platform Designed to Mechanically Destroy Tumors
Histotripsy is the scientific and clinical foundation of HistoSonics’ platform. Unlike thermal ablation systems that use heat to destroy tissue, or radiation-based approaches that damage tumor DNA through ionizing energy, histotripsy relies on focused ultrasound energy delivered in very short, high-amplitude pulses to create acoustic cavitation—essentially a bubble cloud within the targeted tissue. The rapid formation and collapse of those bubbles generates mechanical forces strong enough to break apart and liquefy tissue at a cellular and sub-cellular level. (HistoSonics)
The company argues that this non-thermal, non-invasive mechanism could offer important advantages in the treatment of tumors. Because the procedure does not require incisions, probes, or radiation exposure, it may reduce the risks associated with surgery and other local interventions. HistoSonics also highlights the ability of physicians to monitor treatment in real time using advanced imaging guidance, potentially allowing for precise targeting and immediate visualization of tissue destruction.
The Edison Histotripsy System is the company’s flagship commercial platform and currently the only histotripsy system cleared by the FDA for liver tumor destruction. HistoSonics continues to emphasize that use of the Edison system outside of the liver remains investigational for now, but the company’s development strategy clearly aims to expand that label over time into additional tumor types and organ systems. (Via Ritzau)
Financing to Support Commercial Scale-Up and Regulatory Expansion
The new financing is expected to support several parallel priorities. First, HistoSonics plans to continue expanding the commercial rollout of the Edison system in the liver setting, where physician adoption has been growing and utilization is increasing across high-profile treatment centers. Commercial expansion in medtech often requires substantial investment in physician training, clinical support, reimbursement work, market access, and hospital adoption infrastructure, particularly when a company is introducing a new therapeutic category rather than simply competing within an established one.
Second, the company will use the capital to fund additional clinical development programs. That includes ongoing work in kidney and pancreas, and likely broader efforts to evaluate histotripsy in other organs such as prostate and potentially additional solid tumor settings over time. Earlier financing rounds have already supported studies such as HOPE4KIDNEY, which completed enrollment and is intended to support the kidney indication expansion. The latest round should give HistoSonics additional flexibility to keep moving multiple programs forward in parallel. (HistoSonics)
Third, the financing will help fund regulatory initiatives beyond liver. The kidney submission is already before the FDA, and pancreatic development appears to be moving toward a future filing. Additional capital will be important as HistoSonics builds the clinical evidence, technical documentation, and regulatory infrastructure needed to support new indications in the U.S. and eventually in international markets.
Finally, the round is intended to advance the company’s broader pipeline applications. HistoSonics has consistently described histotripsy as a platform technology rather than a single-product opportunity. That distinction matters because it suggests the company is building toward a diversified portfolio of clinical indications rather than relying on one tumor type or one procedural niche.
Momentum Builds in a Fast-Growing Histotripsy Story
The latest financing arrives during a period of accelerating visibility for HistoSonics. The company has emerged as one of the highest-profile medtech players in focused ultrasound oncology, and its valuation trajectory reflects growing investor confidence in the platform’s potential. From a $102 million Series D financing in 2024, to a $2.25 billion acquisition-led transaction in 2025, to a $250 million growth financing later that same year, and now a fresh round that values the company at $3.75 billion, HistoSonics has rapidly climbed into the upper ranks of privately held medical device companies. (MassDevice)
That momentum is being driven by a combination of factors: a differentiated mechanism of action, growing clinical adoption in liver tumors, a visible pathway to label expansion in kidney and pancreas, and a broader narrative around non-invasive cancer therapies that can complement or potentially reduce reliance on more invasive standards of care.
For investors such as Yosemite, the attraction appears to be the possibility that histotripsy could become a foundational modality across multiple disease settings. For HistoSonics, the challenge now is to translate that promise into repeatable clinical outcomes, broader regulatory clearances, and sustained commercial execution.
Positioning Histotripsy for the Next Stage of Growth
HistoSonics now stands at an important transition point. It has already demonstrated that histotripsy can move from academic concept to FDA-cleared commercial product in liver tumors. The next phase is about proving that the same underlying platform can be extended across other organs and tumor types while maintaining clinical utility, physician confidence, and economic viability.
If the company succeeds, it could carve out an entirely new treatment category in solid tumors—one centered on non-invasive, mechanical tumor destruction rather than surgical resection, heat-based ablation, or radiation. That is a large ambition, but it is precisely the kind of platform story that has attracted high-profile investors and driven HistoSonics’ valuation upward.
With new backing from Reed Jobs and Yosemite, fresh strategic capital, and a pipeline that now stretches beyond liver into kidney and pancreas, HistoSonics is clearly signaling that it sees histotripsy as a technology with the potential to reshape how certain tumors are treated. The coming years will determine how far that vision can go, but the company’s latest financing suggests investors believe the opportunity is large enough to justify building for scale now.
About HistoSonics
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN.
